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Abstract
Background: Insomnia and migraine are closely related; insomnia aggravates migraine symptoms. This study was
conducted to investigate the impact of migraine on the clinical presentation of insomnia symptoms.
Methods: The data of the Korean Headache-Sleep Study (KHSS) were used in the present study. The KHSS is a
nation-wide cross-sectional population-based survey regarding headache and sleep in Korean adults aged 19 to
69 years. If a participant’s Insomnia Severity Index (ISI) score ≥ 10, she/he was classified as having insomnia. The
clinical presentation of insomnia symptoms was assessed using total and subcomponent scores of the ISI.
Results: Of 2695 participants, 290 (10.8%) and 143 (5.3%) individuals were assigned as having insomnia and migraine,
respectively. The proportions of migraine (12.8% vs. 4.4%, p < 0.001) and non-migraine headache (59.0% vs.
39.9%, p < 0.001) were higher among individuals with insomnia compared to those without insomnia. Among
participants with insomnia, total ISI scores were not significantly different among participants with migraine,
non-migraine, and non-headache [median and interquartile range: 13.0 (11.0–17.5) vs. 13.0 (11.0–17.5) vs. 12.0
(11.0–16.0), p = 0.245]. ISI scores for noticeability of sleep problems to others were significantly higher among
participants with migraine [3.0 (2.0–4.0) vs. 2.0 (2.0–3.0), p = 0.011] and non-migraine headache [3.0 (2.0–4.0) vs.
2.0 (2.0–3.0), p = 0.001] compared to those without headache history. Other ISI subcomponent scores did not
significantly differ between headache status groups.
Conclusions: Participants with insomnia had an increased risk of migraine and non-migraine headache
compared to those without insomnia. Among participants with insomnia, overall insomnia severity was not
significantly influenced by the headache status.
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Background
Migraine is a common neurological disorder and affects
5–15% of the general population [1]. Owing to its disab-
ling symptoms, migraineurs encounter disability and de-
creased quality of life [2]. Even in periods without
migraine symptoms, migraineurs may have a fear of de-
veloping a headache because migraine attacks often
cause a failure to perform social obligations at school,
the workplace, or at home [3]. Sleep disturbances are
common complaints among migraineurs [4–6].
Individuals with migraine or headache with sleep distur-
bances often encounter more severe symptoms and de-
crease quality of life [5, 7, 8].
Insomnia is another disorder with high prevalence, af-
fecting 10–30% of the general population [9]. Insomnia
is associated with hypertension, coronary heart disease,
and diabetes, among others [10]. Furthermore, insomnia
in the working age population is one of the factors that
cause a decrease in productivity [11]. Therefore, insom-
nia is an important public health problem like migraine.
Migraine and insomnia exhibit a strong relationship.
Cross-sectional studies have persistently demonstrated a
significant comorbidity for these two disorders in clinical
and population-based studies [12]. Two longitudinal
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studies using a single dataset show a bidirectional co-
morbidity of migraine and insomnia. Individuals have an
increased risk of developing migraine 11 years after the
onset of insomnia and vice versa [13, 14]. The risk for
developing insomnia increases in patients with an in-
creased migraine headache frequency, and the risk for
developing migraine was positively correlated with se-
vere insomnia. Such a strong bidirectional comorbidity
suggests shared pathophysiological mechanisms [15].
According to previous studies, migraineurs have an in-
creased risk of developing insomnia compared to patients
suffering from non-migraine headache and healthy sub-
jects. Furthermore, migraineurs with insomnia present
with a higher headache frequency and increased headache
intensity compared to those without insomnia [8]. Never-
theless, information about the impact of migraine on the
prevalence and clinical presentation of insomnia in a
population-based sample is currently limited. We hypoth-
esized that migraine affects the prevalence and clinical
presentation of insomnia symptoms. The purposes of the
present study were to investigate 1) the prevalence of mi-
graine and insomnia, 2) the impact of migraine on the
prevalence of insomnia, and 3) the impact of migraine on
the clinical presentation of insomnia in a general
population-based sample.
Methods
Study population and survey process
The data of the Korean Headache-Sleep Study (KHSS)
were used in the present study. The KHSS was a
nation-wide, cross-sectional survey regarding headache
and sleep disorder among Korean adults aged 19 to
69 years. It also included items regarding symptoms of
anxiety and depression. The study design, methods, and
process were described in detail previously [6]. In brief,
the KHSS adopted a two-stage clustered random sam-
pling method for all Korean territories except Jeju-do.
This method sampled participants proportionally to the
population distribution and socioeconomic status. Trained
interviewers conducted the survey by face-to-face inter-
views using a questionnaire. All trained interviewers were
employees of Gallup Korea and had previous experience
in social surveys. Data collection of the KHSS was per-
formed from November 2011 to January 2012. The KHSS
was approved by the Institutional Review Board and
Ethics Committee of Hallym University Sacred Heart
Hospital (IRB No. 2011-I077). Written informed consent
was obtained from all participants.
Migraine assessment
Diagnosis of migraine was based on criteria A to D for
migraine without aura in the third edition beta version
of the International Classification of Headache Disorders
(ICHD-3 beta; code 1.1: A, 5 or more attacks in a
lifetime; B, attack duration of 4–72 h; C, any 2 of the 4
typical headache characteristics [i.e., unilateral pain, pul-
sating quality, moderate-to-severe pain intensity, and ag-
gravation by routine physical activity]; and D, attacks
associated with at least one of the following: nausea,
vomiting, or both photophobia and phonophobia) [16].
We did not distinguish between migraine without aura
(code 1.1) and migraine with aura (code 1.2). Therefore,
migraine included both migraine with aura and migraine
without aura. Our survey method has been reported to
have a sensitivity of 75.0% and a specificity of 88.2% [17].
Non-migraine headache assessment
Participants that experienced more than one minute of
headache in the last twelve months but did not satisfy
the criteria for migraine diagnosis were classified as a
distinct non-migraine headache group.
Insomnia assessment
Insomnia was evaluated by using the Insomnia Severity
Index (ISI), which is a self-report questionnaire with the
following seven items: difficulties in sleep onset, difficul-
ties in sleep maintenance, early awakening in the morn-
ing, sleep dissatisfaction, interference of sleep problems
with daily functioning, noticeability of sleep problems to
others, and worries caused by the sleep problems. This
index measures the individual’s perceptions of their sleep
problem by evaluating the severity of the insomnia prob-
lems within the last two weeks. The total ISI score
ranges from 0 to 28 [18]. Participants with a total ISI
score of 10 or more were classified in our study as suf-
fering from insomnia according to a previous epidemio-
logical study [19]. Additionally, we investigated whether
the sleep was usually non-refreshing. We asked partici-
pants to choose from the categories none, mild, moder-
ate, severe, and very severe and graded each response as
0, 1, 2, 3, and 4, respectively.
Statistical analyses
The Kolmogorov-Smirnov test was used to evaluate the nor-
mality of the distribution. After normality was confirmed,
Student’s t-test or analysis of variance was used to compare
continuous variables. If normality was not confirmed, the
Mann-Whitney U test was used to compare differences
between two independent groups. For comparison of ordinal
variables among more than three groups, we used
Kruskal-Wallis test. To adjust for multiple testing, p-values
were calculated using the Bonferroni post hoc test. Categor-
ical variables were compared using the chi-square test. The
significance level was set at p < 0.05 for all analyses. Statistical
analyses were performed using the Statistical Package for
Social Sciences 22.0 (SPSS 22.0; IBM, Armonk, NY, USA).
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Results
Survey
During the survey, interviewers contacted 7430 individ-
uals, and 3144 permitted to participate. Of those, 449 indi-
viduals waived participation, and thus 2695 participants
completed the whole survey (cooperation rate of 36.3%;
Fig. 1). The distributions of age, sex, size of the residential
area, and education level of KHSS participants was not
significantly different from those of the Korean general
population (Table 1).
Prevalence of insomnia and migraine
Of the 2695 participants, 290 (10.8%) participants reported
an ISI score ≥ 10 and were classified as having insomnia.
The ISI score of all participants was [2.0 (1.0–5.0), median
and interquartile range]. Of the 1273 (47.2%) participants,
who reported that they experienced at least one attack of
headache during the last year, 143 (5.3%) participants were
classified as having migraine. Therefore, 1130 (41.9%) were
classified as having non-migraine headache (Table 1).
Prevalence of migraine and non-migraine headache
according to the presence of insomnia
Among the 290 participants with insomnia, 37
(12.8%), 171 (59.0%), and 82 (28.3%) participants were
classified as having migraine, non-migraine headache,
and non-headache, respectively. The prevalence of mi-
graine (12.8% vs. 4.4%, p < 0.001) and non-migraine
headache (59.0% vs. 39.9%, p < 0.001) was significantly
higher among participants with insomnia compared to
that in participants without insomnia (Fig. 2).
Total and subcomponent ISI scores among participants
with insomnia according to the headache status
In the 290 participants with insomnia, the total ISI
score was not significantly different among migraine,
non-migraine headache, and non-headache groups. A
further analysis of the seven ISI subcomponent scores
revealed that only the categories interference with
daily functioning and noticeability of sleep problems
to others exhibited significantly different scores
among the three headache groups. Furthermore, our
additional parameter non-refreshing sleep showed sig-
nificant score differences among these groups. Post
hoc analyses revealed that the scores for noticeability
of sleep problems to others, and non-refreshing sleep
were significantly higher in participants of the
non-migraine headache group than those in the
non-headache group and score for noticeability of
sleep problems to others was significantly higher in
participants of the migraine group than those in the
non-headache group. However, subcomponent for
interference with daily functioning did not show sig-
nificance in post hoc analysis (Table 2).
Prevalence of insomnia according to the headache status
Insomnia prevalence among participants with mi-
graine, non-migraine headache, and non-headache
was 25.9%, 15.1%, and 5.8%, respectively (Fig. 3). The
prevalence of insomnia among migraineurs was sig-
nificantly higher compared to participants with
non-migraine headache (p = 0.001) and non-headache
(p < 0.001).
Fig. 1 Flowchart depicting the participation of subjects in the KHSS
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Table 1 Sociodemographic characteristics of survey participants, the total Korean population, and cases identified as having
migraine, non-migraine headache, and insomnia
Survey participants
N (%)
Total population
N (%)
P Migraine
N, % (95% CI)
Non-migraine headache
N, % (95% CI)
Insomnia
N, % (95% CI)
Gender
Men 1345 (49.3) 17,584,365 (50.6) 0.854a 36, 2.7 (1.8–3.5) 471, 35.0 (32.5–37.6) 117, 8.7 (7.2–10.2)
Women 1350 (50.7) 17,198,350 (49.4) 107, 7.9 (6.5–9.4) 659, 48.8 (46.2–51.5) 173, 12.8 (11.0–14.6)
Age
19–29 542 (20.5) 7,717,947 (22.2) 0.917a 25, 4.5 (2.7–6.2) 231, 42.6 (38.4–46.8) 59, 10.9 (8.3–13.5)
30–39 604 (21.9) 8,349,487 (24.0) 42, 7.0 (4.9–9.1) 269, 44.5 (40.6–48.5) 53, 8.8 (6.5–11.0)
40–49 611 (23.1) 8,613,110 (24.8) 39, 6.5 (4.5–8.4) 277, 45.3 (41.4–49.3) 66, 10.8 (8.3–13.3)
50–59 529 (18.9) 6,167,505 (17.7) 22, 4.1 (2.4–5.9) 204, 38.6 (34.4–42.7) 63, 11.9 (9.1–14.7)
60–69 409 (15.6) 3,934,666 (11.3) 15, 3.9 (2.0–5.7) 149, 36.4 (31.7–41.1) 49, 12.0 (8.8–15.1)
Size of residential area
Large city 1248 (46.3) 16,776,771 (48.2) 0.921a 76, 6.1 (4.8–7.5) 525, 42.1 (39.3–44.8) 136, 10.9 (9.2–12.6)
Medium-to-small city 1186 (44.0) 15,164,345 (43.6) 48, 4.0 (2.9–5.2) 488, 41.1 (38.3–44.0) 125, 10.5 (8.8–12.3)
Rural area 261 (9.7) 2,841,599 (8.2) 19, 7.4 (4.2–10.6) 117, 44.8 (38.8–50.9) 29, 11.1 (7.3–14.9)
Education level
Middle school or less 393 (14.9) 6,608,716 (19.0) 0.752a 22, 5.5 (4.2–7.7) 156, 42.0 (37.1–46.9) 62, 15.8 (12.2–19.4)
High school 1208 (44.5) 15,234,829 (43.8) 60, 5.0 (3.8–6.3) 502, 41.6 (38.8–44.4) 116, 9.6 (7.9–11.3)
College or more 1068 (39.6) 12,939,170 (37.2) 60, 5.6 (4.3–7.0) 457, 42.8 (40.0–45.8) 109, 10.2 (8.4–12.0)
Not responded 26 (1.0) 1, 3.8 (0.0–11.8) 6, 23.1 (5.7–40.4) 3, 11.5 (0.0–24.7)
Total 2695 (100.0) 34,782,715 (100.0) 143, 5.3 (4.5–6.2) 1130, 41.9 (40.0–43.8) 290, 10.8 (9.6–11.9)
aComparison of sex, age group, size of residential area, and educational level distributions between the sample in the present study and the total population
of Korea
N, number; CI, confidence interval
Fig. 2 Comparison of headache type according to the presence of insomnia
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Headache frequency, headache intensity, and impact
of headache according to the presence of insomnia
among participants with migraine and non-migraine
headache
The Visual Analogue Scale (VAS) score for headache
intensity (median [interquartile range], 7.0 [5.0–9.0]
vs. 6.0 [5.0–7.0]; p = 0.003) and the Headache Impact
Test-6 (HIT-6; 60.0 ± 9.5 vs. 52.3 ± 8.4; p < 0.001)
score were significantly higher in migraineurs with
insomnia compared to those in migraineurs without
insomnia. Headache frequency per month was dis-
cernibly different according to the presence of insom-
nia without reaching statistical significance (5.7 ± 8.2
vs. 3.2 ± 5.4, p = 0.093). Among participants with
non-migraine headache, headache frequency per
month, VAS score for headache intensity, and HIT-6
score were significantly higher when insomnia was
present (Table 3).
Discussion
The key findings of the present study were as follows: 1)
The prevalence of migraine and non-migraine headache
was significantly higher among participants with insom-
nia compared to those without insomnia; 2) Among par-
ticipants with insomnia, the total ISI score was not
significantly different among migraine, non-migraine
headache, and non-headache groups and 3) Among par-
ticipants with migraine, the prevalence of insomnia was
Table 2 Total ISI and its subcomponent scores among participants with insomnia in relation to the headache status
Migraine
(N = 37)
Non-migraine headache
(N = 171)
Non-headache
(N = 82)
P
Total ISI score 13.0 (11.0–17.5) 13.0 (11.0–17.0) 12.0 (11.0–16.0) 0.245
Falling asleep 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 0.796
Staying asleep 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 0.671
Early awakening 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 0.303
Satisfaction 4.0 (3.5–4.0) 4.0 (3.0–5.0) 4.0 (3.0–4.0) 0.245
Interference 3.0 (3.0–4.0) 3.0 (2.0–4.0) 3.0 (2.0–3.0) 0.032
Noticeability 3.0 (2.0–4.0)a 3.0 (2.0–4.0)a 2.0 (2.0–3.0) 0.002
Worry 3.0 (2.0–4.0) 3.0 (2.0–4.0) 3.0 (2.0–3.0) 0.364
Non-refreshing sleepb 2.0 (2.0–3.0) 3.0 (2.0–4.0)a 2.0 (1.0–3.0) 0.001
Variables are presented as median (interquartile range)
Kurskal-Wallis test was used to compare among three groups
aSignificantly higher in the post hoc analysis compared to the non-headache group
bNon-refreshing sleep score is not included in the total ISI score
Fig. 3 Comparison of the prevalence of insomnia according to headache type
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higher than participants with non-migraine headache
and non-headache. Migraine symptoms exacerbated with
the presence of insomnia.
There is limited information available about the im-
pact of insomnia on the clinical presentation of head-
ache. It has been reported that in individuals with
headache or migraine, those with insomnia present an
increased symptom severity compared to those without
[13]. Nevertheless, information regarding the impact of
headache or migraine on the clinical presentation of in-
somnia is currently scarce. Our study is the first report
in a population-based setting that individuals with in-
somnia have an increased risk of suffering from migraine
and non-migraine headache. Furthermore, the insomnia
severity as reflected by the total ISI score did not differ
among headache status groups in individuals with in-
somnia (Table 2). These findings suggest that the head-
ache status does not influence the overall severity of
insomnia among affected individuals. In contrast, insom-
nia has a significant impact on the clinical presentation
of migraine. Migraineurs with insomnia experienced a
higher headache intensity and impact of headache
(HIT-6 score) compared to migraineurs without insom-
nia (Table 3).
What could be the underlying mechanism for the dif-
ference between the impact of migraine on insomnia se-
verity and the impact of insomnia on migraine severity?
It is possible that their distinct anatomy and pathophysi-
ology contribute to the contrast findings. Hypothalamus
has been understood to play key regulatory roles both
for migraine and sleep controls. The supraoptic nucleus
in anterior region plays a key role in the regulation of
sleep and arousal. Pain perception was regulated by
arcuate nucleus in tuberal region [20]. Although supra-
optic nucleus and arcuate nucleus are located nearby in
hypothalamus, they have distinctive anatomical loca-
tions. A recent functional magnetic resonance imaging
study showed that posterior hypothalamic activation was
noted during the acute migraine stage [21]. Orexinergic
system acts a regulatory role both in sleep and pain.
Orexin-A and orexin-B were synthesized in hypothal-
amus and promote arousal. Nevertheless, they do differ-
ent roles in pain modulation. Orexin-A is able to inhibit
neurogenic dural vasodilation via activation of the orexin
receptor type 1, resulting in inhibition of prejunctional
release of calcitonin-gene related peptide from trigemi-
nal neurons [22]. In contrast, orexin-B increases the A
and C-fibre responses to dural electrical stimulation as
well as spontaneous activity [23].
Among the ISI subcomponents, the score for noticeability
of sleep problems to others was significantly higher among
participants with migraine and non-migraine headache
compared to participants without headache. Furthermore,
the score for non-refreshing sleep were significantly higher
among participants with non-migraine headache compared
to participants without headache (Table 2). In contrast,
other subcomponent scores including difficulties in sleep
onset, difficulties in sleep maintenance, early awakening,
sleep dissatisfaction, and worries caused by the current sleep
problems were not significantly different. The distinct asso-
ciation of the headache status with only certain subcompo-
nents of insomnia suggests that certain subcomponents are
distinctive from other subcomponents. Further, our findings
are in agreement with the previous findings that nonrestora-
tive sleep (NRS) is a distinctive subtype of insomnia from
other subtypes of insomnia. These studies showed that indi-
viduals with NRS was more frequently associated with day-
time impairment than individuals with difficulty initiation of
sleep (DIS), difficulty maintaining sleep (DMS) and early
morning awakening (EMA) [24–27]. While NRS is reported
to be associated with longer sleep latency, shorter sleep
duration, increased alpha activity during non-rapid eye
movement sleep, longer duration of cyclic alternating pat-
terns and chronic pain condition, information on the dif-
ferences in pathophysiology of NRS from other subtypes
of insomnia is currently sparse [25, 28–30]. Therefore,
more research on pathophysiology of NRS is needed for
better management of NRS.
In the present study, we used the ISI to assess insom-
nia. This psychometric scale includes items for difficulty
in falling asleep, difficulty in staying asleep, and early
awakening which enables the classification of insomnia
subtypes [18]. Although we did not identify insomnia
cases by interviews based on International Classification
of Sleep Disorders, 3rd edition or the Diagnostic and
Statistical Manual of Mental Disorders, 5th edition cri-
teria which are the ‘gold standard’ for the evaluation of
insomnia, we are convinced that we successfully
Table 3 Headache frequency, VAS score of headache intensity, and impact of headache in relation to the presence of insomnia
among participants with migraine and non-migraine headache
Migraine with
insomnia (N = 37)
Migraine without
insomnia (N = 106)
P Non-migraine headache
with insomnia (N = 171)
Non-migraine headache
without insomnia (N = 959)
P
Headache frequency 5.7 ± 8.2 3.2 ± 5.4 0.093 3.7 ± 6.8 2.1 ± 4.9 0.004
VAS scorea 7.0 (5.0–9.0) 6.0 (5.0–7.0) 0.003 5.0 (4.0–7.0) 5.0 (3.0–6.0) < 0.001
HIT-6 score 60.0 ± 9.5 52.3 ± 8.4 < 0.001 50.1 ± 8.6 44.4 ± 6.7 < 0.001
VAS Visual Analogue Scale, HIT-6 Headache Impact Test-6
aVariable is analyzed by Mann–Whitney U test and shown as a median (interquartile range)
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evaluated insomnia because the insomnia prevalence in
the present study is in a similar range found in Asian
countries by previous studies [29, 31, 32].
The present study has some limitations. First, we could
not evaluate whether participants of this study underwent
pharmacological or non-pharmacological treatment for in-
somnia. Second, as this is a cross-sectional study, we could
not investigate changes in insomnia symptoms before and
after migraine treatment. Third, the overall response rate
was not high in our study. However, we used a two-stage
clustered random sampling, proportional to the population
distribution of Korea. Therefore, the distribution of age, sex,
size of residential area, and educational level of our partici-
pants was similar to those of the Korean general population.
In addition, the prevalence of migraine, non-migraine and
insomnia in the KHSS were similar to that of previous stud-
ies [17, 33]. Despite these limitations, there are several
strengths in the present study. First, the impact of migraine
on the severity and clinical presentation of insomnia symp-
toms as well as on the prevalence of insomnia was evalu-
ated. Second, the present study also evaluated the impact of
insomnia on the clinical presentation migraine. Third, the
distributions of age, sex, size of the residential area, and edu-
cation level in this study’s participants were not significantly
different from the general population in Korea. The results
of this study seem to appropriately reflect the characteristics
of the general Korean population.
Conclusions
Subjects with insomnia have an increased prevalence of
migraine and vice versa in a population-based setting.
Although insomnia is associated with increased head-
ache frequency and severity among migraineurs, insom-
nia severity is, apart from some subcomponents, not
significantly influenced by the presence of migraine. Our
findings indicate that migraine and insomnia affect each
other but their asymmetric causal relationship needs fur-
ther investigation in future studies.
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